Statistics released this year by the American Society of Plastic Surgeons (ASPS) reveal high demand for body shaping options, with a spike in noninvasive fat reduction procedures in 2018.
Nonsurgical fat reduction device choices are taking the market by storm, with technologies that target fat via cryolipolysis, laser lipolysis or radiofrequency. To get a pulse on the current state of the noninvasive fat reduction market, we asked providers what they’re using and why.
Cryolipolysis on Top
Nonsurgical fat reduction treatments, like CoolSculpting (Allergan), are taking center stage, while Kybella (deoxycholic acid, Allergan) takes a back seat, according to dermatologist and cosmetic surgeon Joel Schlessinger, M.D.
“While Kybella hasn’t turned out to be the blockbuster that many thought it would be, CoolSculpting has filled the void dramatically. With new treatment heads and protocols, CoolSculpting has significantly improved,” Dr. Schlessinger says.
The most notable change, according to Dr. Schlessinger, has been the benefits of using CoolSculpting’s CoolMini on the chin area.
“I think that’s the gateway procedure for fat reduction for most of my patients. They come in for the chin and submental area and during the conversation express interest in other areas,” Dr. Schlessinger says.
And the updated CoolSculpting treatment protocol has boosted patient satisfaction.
“When CoolSculpting was introduced 10 years ago there were some fairly optimistic expectations for CoolSculpting and fairly minimal approaches to getting these optimistic results. They thought that perhaps one session alone might yield optimal results which was clearly not possible,” he says. “Now we explain to our patients that two and perhaps even three sessions are necessary for the desired result. This allows us to set the expectations more appropriately from the outset.”
Dr. Schlessinger says he has been remarkably satisfied with CoolSculpting’s safety, with one exception.
“The one thing that has occasionally occurred is paradoxical adipose hyperplasia in a few patients. In those patients, we’ve taken one-half of the dollars spent on CoolSculpting and put them toward tumescent liposuction. The patients have been very pleased,” Dr. Schlessinger says.
Evolutions in laser and RF devices
SculpSure (Cynosure) is marketing its “WarmSculpting” approach, using targeted laser energy to noninvasively heat fat cells.
Hologic's Cynosure division announced July 26, 2019, that it launched a petite mask for SculpSure submental treatments, which are FDA cleared for patients with a body mass index (BMI) up to 49 — the highest BMI clearance on the market for submental treatments, according to Cynosure.
Drs. Moore, Jeneby, Engleman, Larrabbee and Rivkin report no relevant disclosures. Dr. Schlessinger has performed clinical trials for Liposonix, Ultrashape and Kybella. Dr. Fromowitz is a speaker for Cutera. Dr. Kilmer has received research support from and has been a medical advisory board member with Cutera (stock options too), Cytrellis (stock options) Alastin, Allergan, Dominion, Pulse Biosciences, Lumenis Lutronic, Merz, Sciton, Sienna Labs, Solta/Valeant (advisory board only) and Syneron/Candela. She has received research support in the past year from Galderma, BTL, R2 Derm and Revance. She has stock in Avava and HintMD.